Cargando…

Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment

Objective: The microsatellite status and tumor immune microenvironment have a remarkable influence on tumor immunotherapy. This study was performed to investigate programmed cell death protein 1/programmed death ligand 1 (PD1/PDL1) expression and their correlations with CD8+ T cell/CD68+ macrophage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yan-li, Gong, Yuehua, Lv, Zhi, Li, Liang, Yuan, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890312/ https://www.ncbi.nlm.nih.gov/pubmed/33613757 http://dx.doi.org/10.7150/jca.40500

Ejemplares similares

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
por: Liu, Jingwei, et al.
Publicado: (2020)

Flow Cytometry-Assessed PD1/PDL1 Status in Tumor-Infiltrating Lymphocytes: A Link With the Prognosis of Diffuse Large B-Cell Lymphoma
por: Chen, Zihang, et al.
Publicado: (2021)

Infiltration of Immunoinflammatory Cells and Related Chemokine/Interleukin Expression in Different Gastric Immune Microenvironments
por: Wang, Ang, et al.
Publicado: (2020)

Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment
por: Quan, Qiuying, et al.
Publicado: (2023)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma
por: Stenzel, Philipp J., et al.
Publicado: (2019)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
por: Safi, Mohammed, et al.
Publicado: (2020)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αPDL1 in ovarian cancer
por: Wang, Shourong, et al.
Publicado: (2023)

Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance
por: Zhang, An Zhi, et al.
Publicado: (2022)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

CSF1R is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in the Gastric Cancer Microenvironment
por: Chen, Di, et al.
Publicado: (2021)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
por: Świderska, Janina, et al.
Publicado: (2021)

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction
por: Patil, Sachin P., et al.
Publicado: (2022)

Immunohistochemical Expression of Programmed Death Ligand-1 (PDL-1) in Colorectal carcinoma and Its Correlation with Stromal Tumor Infiltrating Lymphocytes
por: ELfishawy, Mona, et al.
Publicado: (2020)

B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism
por: Liu, Xingluo, et al.
Publicado: (2003)

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
por: Koirala, Pratistha, et al.
Publicado: (2016)

A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
por: Gong, Chang, et al.
Publicado: (2017)

Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis
por: Dhupkar, Pooja M, et al.
Publicado: (2015)

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer
por: Ye, Qing, et al.
Publicado: (2021)

Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients
por: Wu, Yumin, et al.
Publicado: (2022)

Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas
por: Choi, Euno, et al.
Publicado: (2020)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers
por: Erdogdu, Ibrahim Halil
Publicado: (2019)

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022)

Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment
por: Lv, Ji, et al.
Publicado: (2019)

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
por: Yin, Huanhuan, et al.
Publicado: (2020)

Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma
por: Arafa, Mohammad, et al.
Publicado: (2022)

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment
por: Ailia, Muhammad Joan, et al.
Publicado: (2023)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
por: Caldwell, Charles, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_142gdqpo88olk6ldc9i4et82p3